Disparities in the presence of driver mutations and response to tyrosine kinase inhibitors in young patients with lung cancer

被引：0
|
作者：
Edwards, Kyle
Rose, Brandon
Lopes, Gilberto
Rodriguez, Estelamari
Olazagasti, Coral
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-A106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A106
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Rachiglio, Anna Maria
    Fenizia, Francesca
    Piccirillo, Maria Carmela
    Galetta, Domenico
    Crino, Lucio
    Vincenzi, Bruno
    Barletta, Emiddio
    Pinto, Carmine
    Ferrau, Francesco
    Lambiase, Matilde
    Montanino, Agnese
    Roma, Cristin
    Ludovini, Vienna
    Montagna, Elisabetta Sara
    De Luca, Antonella
    Rocco, Gaetano
    Botti, Gerardo
    Perrone, Francesco
    Morabito, Alessandro
    Normanno, Nicola
    CANCERS, 2019, 11 (03):
  • [22] Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
    Nicos, Marcin
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Chmielewska, Izabela
    Wojcik-Superczynska, Magdalena
    Reszka, Katarzyna
    Kieszko, Robert
    Gora-Florek, Anna
    Dudek, Malgorzata
    Swiniuch, Daria
    Papiewski, Wojciech
    Calka, Paulina
    Ciesielka, Marzanna
    Ramlau, Rodryg
    Milanowski, Janusz
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (06) : 1496 - 1500
  • [23] Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
    Marcq, Marie
    Vallee, Audrey
    Bizieux, Acya
    Denis, Marc G.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (07) : E49 - E50
  • [24] Reply to: Lung Cancer in Young Patients: The Importance of Assessing Driver Mutations and Treatment Strategies
    Marco Galvez‑Nino
    Lung, 2020, 198 : 427 - 428
  • [25] Reply to: Lung Cancer in Young Patients: The Importance of Assessing Driver Mutations and Treatment Strategies
    Galvez-Nino, Marco
    LUNG, 2020, 198 (02) : 427 - 428
  • [26] Tumor Heterogeneity for Assessment of Response to Tyrosine Kinase Inhibitors in Patients with Thyroid Cancer
    Bundschuh, R. A.
    Hartl, J.
    Zsoter, N.
    Papp, L.
    Biko, J.
    Buck, A. K.
    Lapa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S240 - S240
  • [27] Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
    Marchetti, Antonio
    Palma, John F.
    Felicioni, Lara
    De Pas, Tommaso M.
    Chiari, Rita
    Del Grammastro, Maela
    Filice, Giampaolo
    Ludovini, Vienna
    Brandes, Alba A.
    Chella, Antonio
    Malorgio, Francesco
    Guglielmi, Flavio
    De Tursi, Michele
    Santoro, Armando
    Crino, Lucio
    Buttitta, Fiamma
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) : 1437 - 1443
  • [28] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [29] Lung cancer-derived EGFR mutations affect responses to tyrosine kinase inhibitors, but not to monoclonal antibodies
    Dechant, M.
    Peipp, M.
    Schneider-Merck, T.
    Beyer, T.
    van Bueren, J. J. Lammerts
    Bleeker, W. K.
    Parren, P. W.
    van de Winkel, J. G.
    Valerius, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: Impact of primary or secondary mutations
    Sakurada, Akira
    Shepherd, Frances A.
    Tsao, Ming-Sound
    CLINICAL LUNG CANCER, 2006, 7 : S138 - S144
12345